Biomarkers of Lichen Sclerosus

Overview

Lichen sclerosus (LS) is a skin condition of the external genitals (vulva) of women. LS causes vulvar itching, pain, and burning. In addition, LS causes scarring of the vulva which may cause significant lack of sexual pleasure or pain. Lastly, 4-6% of women with LS will develop vulvar cancer. The purpose of this study is to learn the gene expression file changes in skins affected by LS as compared to normal skins in order to discover the mechanism of the LS, and further to develop effective drugs to treat the condition.

Full Title of Study: “Discovery and Validation of Biomarkers of Lichen Sclerosus”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: November 26, 2019

Detailed Description

Lichen sclerosus (LS) is a chronic, lymphocyte mediated cutaneous disorder affecting approximately one in seventy women. Presenting symptoms may include intense pruritis, pain, burning, and dyspareunia. This disorder may affect any area of the skin, but has a notable predilection for the female genital region, in particular, the vulva, per anal area and the groin. Affected females outnumber affected males by 13:1. Typically, the patient is a menopausal woman, but prepubertal girls and women of all ages may be affected. The typical lesions of lichen sclerosus are white plaques and papules, often with areas of ecchymosis, excoriation, and ulceration. Often, there is destruction of the vulvar architecture with scarring of the clitoral prepuce, resorption of the labia minora, and narrowing of the introitus. Vulvar lichen sclerosus has a 4%-6% transformation malignant rate and women with the disease are at a 250-fold increased risk for developing vulvar carcinoma than women without lichen sclerosus. While the exact etiology of LS is as yet unknown, there is at least a suggested genetic component as evidenced by case reports of familial LS, findings of associations with HLA antigens, and high rates of concordance with other autoimmune disorder. The purpose of this study is to determine the differences in the genomic/proteomic profiles between LS and normal skin biopsies for women with active vulvar lichen sclerosus in order to identify potential biomarkers that can be used for the prevention, early diagnosis and effective treatment for LS. The study will aim to identify genes/proteins/glycoproteins biomarkers that are associated with LS, select biomarkers associated with LS either individual candidate biomarker or as a panel, validate the identified candidate biomarkers for LS using targeted analysis of candidate biomarkers from independent LS specimen sets, develop assays to determine the clinical utilities of the identified biomarkers as minimum invasive tests for the early detection of LS and determine the clinical utility of biomarkers for biopsy-based tissue tests for LS diagnosis and treatment.

Clinical Trial Outcome Measures

Primary Measures

  • Differential gene expression between LS and normal vulvar skin tissue
    • Time Frame: 1-2 year
    • Gene expression obtained from biopsies via Next Generation Sequencing (RNASeq)
  • Differential protein expression between LS and normal vulvar skin tissue
    • Time Frame: 1-2 year
    • Protein expression obtained from biopsies via Western blot
  • Identification of tissue-derived glycoproteins in serum
    • Time Frame: 1-2 years
    • Glycoproteins identified via glycoproteomic technologies

Participating in This Clinical Trial

Inclusion Criteria

  • 18-75 of age – Diagnosis of active, Histologically proven, vulvar lichen sclerosus Exclusion Criteria:

  • Under the age of 18 or over the age of 75. – Participants who are pregnant at the time of recruitment – If, in the clinical opinion of Dr. Andrew Goldstein, she: – does not have active LS – has active infection – has evidence of any other dermatologic disease of the vulva – has evidence of neoplastic disease of the vulva – If, in the opinion of Dr. Andrew Goldstein, they will be unable to keep the biopsy sites clean until they heal. – If the biopsy specimen sent to dermatopathology is not confirmatory for active lichen sclerosus then the specimens obtained from that patient will be excluded from the study.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 75 Years

Investigator Details

  • Lead Sponsor
    • Center for Vulvovaginal Disorders
  • Collaborator
    • Gynecologic Cancer Research Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrew T. Goldstein, MD, Study Investigator – Center for Vulvovaginal Disorders
  • Overall Official(s)
    • Charles Macri, MD, Principal Investigator, George Washington University School of Medicine and Health Sciences
    • Sidney Fu, MD, PhD, Principal Investigator, George Washington University School of Medicine and Health Sciences
    • Andrew T Goldstein, MD, Principal Investigator, The Center for Vulvovaginal Disorders
  • Overall Contact(s)
    • Andrew T Goldstein, MD, 4102790209, obstetrics@yahoo.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.